Shares of Phreesia, Inc. (NYSE:PHR – Get Rating) have been assigned a consensus recommendation of “Moderate Buy” from the fourteen analysts that are covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 12-month price objective among […]
Phreesia (NYSE:PHR – Get Rating) had its price objective dropped by equities research analysts at KeyCorp from $45.00 to $40.00 in a research report issued on Thursday, The Fly reports. KeyCorp’s target price points to a potential upside of 29.45% from the company’s previous close. Several other research firms have also commented on PHR. JMP […]
CI Investments Inc. lowered its stake in Phreesia, Inc. (NYSE:PHR – Get Rating) by 8.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 212,365 shares of the company’s stock after selling 19,000 shares during the period. CI Investments Inc.’s holdings […]
Phreesia, a leader in patient intake, outreach and activation, has been selected by Modern Healthcare as one of the 2023 Best Places to Work in Healthcare. This is the seventh time Phreesia has been. | May 17, 2023
Phreesia is pleased to announce that Hilary Hatch, PhD, Phreesia’s Chief Clinical Officer, has been named as one of the 2023 PM360 ELITE 100 by healthcare-marketing trade publication,. | May 16, 2023